All News

Yet Khor discusses why a 20% CT emphysema threshold, not spirometry alone, best identifies CPFE and predicts outcomes in fibrotic ILD.

A national study found comorbidities may drive worse long-term survival among patients with MASH awaiting or undergoing liver transplant.

Tozorakimab cut moderate/severe COPD exacerbations up to 34% in the phase 3 trials OBERON and TITANIA across smoking status and eosinophil levels.

FDA approved zilganersen (ZANVASTRO), the first disease-modifying treatment for Alexander disease, based on pivotal trial data.

Despite positive data, the study authors call for prospective validation before PRO burden is incorporated into broader risk-stratification approaches.

Lung transplant candidates are aging rapidly, while cystic fibrosis decline in children shifts pediatric transplant toward sicker, more complex patients.

CMS awarded NY, RI, and MI Rural Health Transformation Program funding to expand rural health care workforce and technology access.

Cleveland heart failure experts discuss the new HFpEF pathway, CKM screening gaps, and drug access barriers.

COPD care gaps, financial strain, and sex disparities negatively impact patient outcomes and quality of life, according to the findings of 2 posters.

Tozorakimab dampened antiviral, allergic, and neutrophilic inflammation pathways in COPD airways, new phase 2a data show.

COPD kills at rates rivaling heart failure and exceeding prostate and breast cancer, per a new study and US mortality data.

A deep learning model detected colorectal cancer on noncontrast CT with 86.6% to 88.2% real-world sensitivity.

Late-breaking HELIOS-B subgroup data show mortality and CV benefits held regardless of baseline tafamidis use, per results at ESC Congress 2026.

gMG rescue therapy hinges on hospital access; grocery aid cuts diabetes complications; trials, CAR T strain oncology; myeloma faces logistics barriers.

Bioethicists say Kalshi's FDA and clinical trial betting markets risk bias, insider trading, and misleading signals about drug value.

Community oncologists are steadily adopting bispecific antibodies for myeloma, but advance planning and tocilizumab remain key to safe access.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Keith Bellovich, DO, of Strive Health, discusses how the new CKM guideline unifies cardiology, nephrology, and endocrinology care.

August authors Jeff Romine, PhD, and Kofi Essel, MD, MPH, found grocery assistance linked to fewer diabetes complications and better medication adherence.

Whether these findings will translate into a change in treatment guidelines remains to be seen.

A researcher explains why cardiac diagnoses, not all-cause mortality, are the most reliable finding in her vaccine-safety study.

A randomized crossover trial found dose-dependent driving impairment from THC edibles at blood concentrations below common per se limits.

Ropeginterferon alfa-2b-njft is expected to be available immediately.

Irritants, cleaning products, and mites tracked with SHE in 56,978 Dutch adults, although the exposure tool was built for occupational asthma.

A cardiovascular researcher explains why her team compared cardiac risks of COVID-19 infection and vaccination head-to-head.

Experts discuss what SCAN Health Plan's new Medicare Advantage (MA) partnership with Costco could mean for beneficiaries, competition, and costs.

Ninety-six percent of the study population also had confirmed chronic traumatic encephalopathy on autopsy.

Poor cardiovascular health, especially high BMI and poor sleep, is linked to a substantially higher risk of overactive bladder, new data show.